We already showed that the plant sterol guggulsterone has been reported to inhibit nuclear factor-kB (NF-kB) signaling in intestinal epithelial cells (IECs) and to attenuate dextran sulfate sodium (DSS)-induced colitis. This study investigates the anti-inflammatory effects of novel guggulsterone derivatives on IEC and preventive and therapeutic murine models of DSS-induced colitis. Novel guggulsterone derivates with high lipophilicity were designed and four derivates, including GG-46, GG-50B, GG-52, and GG-53, were synthesized. Two guggulsterone derivatives, GG-50B and GG-52, significantly inhibited the activated NF-kB signals and the upregulated expression of interleukin-8 (IL-8) in COLO 205 cells stimulated with tumor necrosis factor-a (TNF-a). Pretreatment with GG-50B and GG-52 attenuated the increased IkB kinase (IKK) and IkBa phsophorylation induced by TNF-a. In preventive and therapeutic models of murine colitis, administration of GG-52 significantly reduced the severity of DSS-induced colitis, as assessed by disease activity index, colon length, and histology. In contrast, GG-50B did not show a significant reduction in the colitis severity. Moreover, the efficacy on attenuating colitis by GG-52 was comparable to that by sulfasalazine or prednisolone. These results indicate that the novel guggulsterone derivative GG-52 blocks NF-kB activation in IEC and ameliorates DSS-induced acute murine colitis, which suggests that GG-52 is a potential therapeutic agent for the treatment of inflammatory bowel diseases.
Inflammatory bowel disease (IBD) is a complex group of chronic relapsing inflammatory disorders of the intestinal tract. IBD comprises two prototypes, ulcerative colitis and Crohn's disease. Although the etiology of IBD remains unknown, current evidence strongly suggests that IBD arises from a disruption of mucosal immune homeostasis in genetically susceptible individuals, resulting in altered processing of enteric antigens, pathogenic T-cell activation, and chronic inflammation. 1, 2 Despite the significant advances in understanding the underlying genetic basis and pathogenesis of the diseases, no drugs used to treat IBD have a non-relapsing cure rate, and few non-toxic therapeutic options are currently able to modulate intestinal inflammation. Therefore, the discovery of new and specific therapies for IBD is still a challenge. 3 The intestinal epithelium serves as a barrier between luminal triggers and the host. Impaired barrier function may lead to increased uptake of luminal antigens that promote mucosal inflammation. 4 The intestinal barrier is formed by epithelial cells and junctional complexes including tight junctions. Defects of the barrier are directly related to increased intestinal epithelial permeability and uptake of luminal antigens that result in IBD. [5] [6] [7] Therefore, drugs that can reverse defects of the barrier need to be developed.
Activation of the proinflammatory gene transcriptional program in intestinal epithelial cells (IECs) when challenged by the bacterial products, including lipopolysacchride, or various inflammatory cytokines such as tumor necrosis factor-a (TNF-a) and interleukin (IL)-1b, is associated with acute or chronic intestinal inflammation. 8 Activation of transcription factor nuclear factor-kB (NF-kB) leads to upregulation of the expression of proinflammatory genes involved in IBD development. 9 In addition, the increase in intestinal epithelial tight junction permeability requires NF-kB activation. 10 Therefore, NF-kB activation in IECs seems to be strongly associated with IBD, suggesting that modulation of NF-kB signaling could be a potential target for the treatment of IBD. 9, 11, 12 Recently, we showed that guggulsterone [4,17(20) -pregnadiene-3, 16 -dione] blocks NF-kB signaling pathway and attenuates acute murine colitis. 13 Guggulsterone is an active compound extracted from the gum resin of the tree Commiphora mukul that has been used for thousands of years to treat arthritis, obesity, lipid metabolism disorders, hypothyroidism, and inflammation in the traditional Indian medicinal system. 14 However, there is a possibility that adsorption of guggulsterone into the blood may induce serious adverse effects, even if guggulsterone is administered via an oral or rectal route. A possible solution to this critical drawback is the development of chemical derivatives. 15 In this study, we report the design of novel guggulsterone derivatives and investigate the effect of these derivatives on TNF-a-induced NF-kB signaling in IECs and preventive and therapeutic murine models of dextran sulfate sodium (DSS)-induced colitis.
MATERIALS AND METHODS

Biosynthesis of Guggulsterone Derivatives and Cell Culture
We synthesized four guggulsterone derivatives: GG-46, GG-50B, GG-52, and GG-53 ( Figure 1 ). Biosynthesis was performed at R&D Center, Choongwae Pharma (Hwasung, Korea). The derivatives were dissolved in DMSO as a 50 mM stock solution and stored at À201C. The toxicity test of GG compounds was performed at ChemOn (Yongin, Korea). The human colon cancer cell line COLO 205 [KCLB 10222, Korean Cell Line Bank (KCLB), Seoul, Korea] was used between passages 20 and 40. 16 Cells were grown in DMEM (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine serum, 2 mM glutamine and antibiotics (100 unit/ml of penicillin and 100 mg/ml of streptomycin). Cells were seeded at 0.5-2 Â 10 6 cells per well onto six-well plates and allowed to attach overnight. After 12 h of serum starvation, cells were pretreated for 24 h with guggulsterone derivatives or with DMSO vehicle, after which cells were stimulated with TNF-a (10 ng/ml) for the indicated period.
Real-Time RT-PCR and ELISA Total cellular RNA was extracted from COLO 205 cells using Trizol (GIBCO BRL, Gaithersburg, MD, USA). Real-time PCR for IL-8, MCP-1, and b-actin mRNA was performed as described earlier. 13, 17 Briefly, 1 mg of extracted RNA was reverse transcribed and amplified using the SYBR green PCR master mix and an ABI prism 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA). Primers designed using Primer Express v2.0 were purchased from Applied Biosystems. 13 Amplifications were performed in triplicate, and the data were normalized vs b-actin for human IL-8 or MCP-1. The amounts of human IL-8 and mouse macrophage-inflammatory protein (MIP)-2 were measured using a commercially available ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Colonic tissues were homogenized with 0.3 ml PBS containing complete protease inhibitor mixture (Roche, Tokyo, Japan). For measuring concentration of MIP-2, homogenates were centrifuged at 12 000 g for 15 min, and the supernatants were filtered through a 0.22-mm filter to remove any contaminants. PathScans Phospho-NF-kB p65 (Ser536) sandwich ELISA kit were purchased from Cell Signaling Technology (Danvers, MA, USA).
Electrophoretic Mobility Shift Assay
Cells were harvested and nuclear extracts were prepared as described earlier. 18 The concentrations of proteins in the extracts were determined using a Bradford assay (Bio-Rad, Hercules, CA, USA). Electrophoretic mobility shift assay (EMSA) was performed using an assay kit (Promega, Madison, WI, USA) as described earlier. 18 In brief, 5 mg of nuclear extract was incubated for 30 min at room temperature with a g 32 P-labeled oligonucleotide probe (5 0 -AGT TGA GGG GAC TTT CCC AGG C-3 0 ) corresponding to a consensus NF-kB-binding site. After incubation, both bound and free DNA was resolved on 5% polyacrylamide gels.
Transfection and Reporter Assay
Reporter plasmids, including pIL8-luciferase, p2x NF-kBluciferase, pb-actin-and pRSV-b-galactosidase-luciferase transcriptional reporters, were provided by Dr Kagnoff of the University of California, San Diego, USA, 18, 19 and the pMCP-1-luciferase transcriptional reporter was provided by Dr Ik-San Kim at Seoul National University College of Medicine, Seoul, Korea. 20, 21 Cells in six-well dishes were transfected with 1.5 mg of plasmid DNA using Lipofectamine Plus reagents (Invitrogen, Carlsbard, CA, USA) as described Figure 1 Chemical structure of novel guggulsterone derivatives.
GG-52-induced attenuation of colitis JM Kim et al earlier. 22 The transfected cells were incubated for 24 h at 371C in a 5% CO 2 incubator. Cells were then harvested and wholecell lysates were prepared as described earlier. 22 Luciferase activity was determined in accordance with the manufacturer's instructions (Tropix, Bedford, MA, USA) and luminescence was quantitated for 10 s using a luminometer (MicroLumat Plus, Berthold GmbH KG, Bad Wildbad, Germany). Luciferase activity was determined and normalized relative to b-galactosidase expression. 22 Immunoblot Analysis Cells were washed with ice-cold PBS and lysed in 0.5 ml/well lysis buffer [150 mM NaCl, 20 mM Tris at pH 7.5, 0.1% Triton X-100, 1 mM phenylmethyl sulfonyl fluoride (PMSF), and 10 mg/ml aprotinin]. A measure of 15-50 mg of protein per lane was size fractionated on a 6% polyacrylamide minigel, and electrophoretically transferred to a nitrocellulose membrane (0.1-mm pore size). Specific proteins were detected using mouse IkBa, anti-human phospho-IkBa and actin (Cell Signaling Technology, Beverly, MA, USA) as primary antibodies and peroxidase-conjugated anti-mouse IgG as a secondary antibody. Specifically bound peroxidase was detected by enhanced chemiluminescence (ECL system; Amersham Life Science, Buckinghamshire, UK) and exposure to X-ray film.
IjB Kinase Assay
IkB kinase (IKK) activity on IkBa phosphorylation was determined by using a commercially available HTScan IKK-b kinase assay kit (Cell Signaling Technology) according to the manufacturer's instructions. Briefly, cells treated with guggulsterone derivatives were washed with ice-cold PBS. Whole-cell extracts were prepared using lysis buffer (150 mM NaCl, 20 mM Tris at pH 7.5, 0.1% Triton X-100, 1 mM PMSF, and 10 mg/ml aprotinin), after which lysates were cleared by centrifugation at 14 000 r.p.m. for 10 min at 41C. Levels of IKK activity were measured by colorimetric ELISA as per the manufacturer's instructions. 23 The Preventive Model of Acute Murine Colitis Animal studies were performed using specific pathogen-free mice as described earlier. 13 Specific pathogen-free mice (C57BL/6NCrljBgi mice, 20-25 g, 7-8 weeks) were purchased from Orient Experimental Animal, Seoungnam, Korea. Animals were maintained on a 12-h light/12-h dark cycle under the specific pathogen-free conditions. The mice had ad libitum access to a standard diet and water until reaching the desired age (8-9 weeks) and/or weight (18-21 g). All procedures using animals were reviewed and approved by the Institutional Animal Care and Use Committee of Seoul National University Hospital.
In vivo studies using a preventive murine model were performed as described earlier. 13 Mice were administered 4% DSS (MP Biochemicals, Irvine, CA, USA) dissolved in water that was filter-purified for 5 days. The guggulsterone derivatives GG-50B and GG-52 were suspended in 0.5% methylcellulose solution (vehicle) and administered once daily by oral gavage (50 or 200 mg/kg/day) for 7 days beginning 2 days before DSS exposure. As a negative control, DSStreated mice received the vehicle in a comparable volume (10 ml/kg) by the same route. In the next step, to compare the effect of guggulsterone derivative GG-52 with well-known IBD drugs, sulfasalazine (Sigma, 200 mg/kg/day), prednisolone (Sigma, 1 mg/kg/day), and GG-52 (200 mg/kg/day) were administered once daily by oral gavage for 7 days beginning 2 days before DSS exposure. As there was no difference in water intake between the different treatment groups, the mice seemed to drink the same amount of DSS.
The Therapeutic Model of Acute Murine Colitis
To examine whether GG-52 can show the therapeutic effect on DSS-induced colitis, a therapeutic murine model was used as described earlier. 24 Briefly, mice were given 4% DSS for 5 days to establish acute colitis, after which the guggulsterone derivative GG-52 suspended in 0.5% methylcellulose solution (vehicle) was administered once daily by the rectal route (25 or 100 mg/kg/day) for 3 days.
TNBS-Induced Acute Murine Colitis
Trinitrobenzene sulphonic acid (TNBS)-induced experimental colitis was performed in C57BL/6 mice as described earlier. 25 In brief, mice were anesthetized with zoletil, and a 3.5 F catheter was inserted intrarectally 4 cm from the anus. To induce colitis, 100 ml of 3 mg TNBS (Sigma) in 50% ethanol was slowly administered into the lumen via the catheter. GG-52 was suspended in 0.5% methylcellulose solution (vehicle) and administered once daily by oral gavage (200 mg/kg/day) for 7 days beginning 2 days before TNBS exposure. As a negative control, mice received the vehicle in a comparable volume by the same route.
Macroscopic Assessment and Histological Evaluation of Colonic Damage
Mice were checked daily for behavior, water/food consumption, body weight, stool consistency, and the presence of gross blood in the stool or at the anus. After the animals were killed, colonic damage was quantified by a clinical score assessing weight loss, stool consistency, and gross rectal bleeding according to Cooper et al. 26 The disease activity index (DAI) was calculated based on the following parameters as described earlier: 24 stool consistency (0, normal; 2, loose; 4, diarrhea), gross bleeding (0, absence; 2, blood tinged; 4, presence), and weight loss (0, none; 1, 1%B5%; 2, 5%B10%; 3, 10%B20%; 4, more than 20%). DAI ¼ (stool consistency þ gross bleeding þ weight loss)/3. For each animal, histological examination was performed on three samples of the distal colon. In DSS-induced colitis, all histological quantification was performed in a blinded manner using the scoring system described earlier. 27 Briefly, three independent parameters were measured: the severity of inflammation, the extent of injury, and crypt damage. The score of each parameter was multiplied by a factor reflecting the percentage of tissue involvement, and all numbers were summed. In TNBSinduced colitis, inflammation was graded from 0 to 4 as follows in a blinded manner: 0, no signs of inflammation; 1, low leukocyte infiltration; 2, moderated leukocyte infiltration; 3, high leukocyte infiltration, moderate fibrosis, high vascular density, thickening of the colon wall, moderate goblet cell loss, and focal loss of crypts; and 4, transmural infiltrations, massive loss of goblet cells, extensive fibrosis, and diffuse loss of crypts. 28 Immunohistochemical Analysis Immunohistochemical analysis for phosphorylated IKKa was performed as described earlier. 13 Briefly, for the microwave antigen retrieval procedure, slides were immersed in 10 mM citrate buffer (pH 6.0) in a clean polyethylene chamber in a full-powered microwave for 10 min and were then cooled for 10-20 min. After washing with PBS, the sections were stained with rabbit polyclonal antiphosphorylated IKKa antibody (Cell Signaling Technology) in an automated staining system (Tech Mate 1000 TM, Ventana, Tucson, AZ, USA) according to the manufacturer's recommendations. 13 
Statistical Analysis
Differences between groups were compared using an analysis of variance with Bonferroni correction. P-values o0.05 were considered statistically significant.
RESULTS
The Guggulsterone Derivatives GG-50B and GG-52 Inhibit the Expression of IL-8 and MCP-1 in COLO 205 Cells To determine whether guggulsterone derivatives could reduce inflammatory responses, chemokine mRNA expression was evaluated in COLO 205 cells stimulated with TNF-a. As shown in Figure 2a GG-52-induced attenuation of colitis JM Kim et al
IECs. 29 As we already showed that guggulsterone inhibits NF-kB activity in IECs, we asked whether the guggulsterone derivatives GG-50B and GG-52 could prevent TNF-ainduced NF-kB activity. For this experiment, the NF-kB DNA-binding activity was determined by EMSA. Pretreatment with GG-50B and GG-52 reduced the NF-kB DNAbinding activity in a dose-dependent manner (Figure 4a ). To confirm this result, a reporter gene assay was performed. As shown in Figure 4b , pretreatment of cells with GG-50B and GG-52 decreased the TNF-a-induced NF-kB activity significantly.
Guggulsterone Derivatives GG-50B and GG-52 Inhibit NF-jB Signaling in IEC by Blocking IKK TNF-a strongly induced IkBa phosphorylation/degradation in COLO 205 cells, whereas IkBa phosphorylation/degradation was suppressed in GG-50B and GG-52-treated cells (Figure 5a) . To determine the effect of the two guggulsterone derivatives on IKK activity, an HTScan IKK-b kinase assay was performed. As shown in Figure 5b , stimulation of COLO 205 cells with TNF-a resulted in an increase of IKK activity, whereas pretreatment of cells with GG-50B or GG-52 significantly reduced the TNF-a-induced IKK activity. These results indicate that the guggulsterone derivatives GG-50B and GG-52 can inhibit NF-kB signaling pathway by blocking IKK activity. GG-52-induced attenuation of colitis JM Kim et al severity of DSS-induced colitis, although a few indices showed improvement (Table 1 ). In addition, administration of GG-50B did not reduce the microscopic histological grading (Figure 6a ). In contrast, GG-52 (200 mg/kg q.d.) reduced both clinical and macroscopic inflammatory indices significantly (Table 1) , and resulted in clear and significant attenuation of acute colitis histologically (Figure 6a and b) . Furthermore, the DSS-induced phospho-NF-kB p65 and secretion of MIP-2, a mouse homologue of IL-8, were significantly decreased in the GG-52-pretreated mice (Figure 7a and b). As our data of in vitro study showed that GG-52 could exert its anti-inflammatory effects by blocking IKK activity in IEC, we investigated this signaling in DSS-colitis model to reconfirm it in vivo. To determine IKK activity in the in vivo model of colitis, immunohistochemistry was performed on colon sections for the mice. As shown in Figure 7b , DSS colitis was accompanied by an increased expression of phophorylated IKK in the colonic mucosa and submucosa. In contrast, IKK phosphorylation was markedly reduced in the presence of GG-52 (Figure 7c ).
The Guggulsterone Derivative GG-52 Attenuates Acute Colitis in a Therapeutic Murine Model As our earlier results showed that the guggulsterone derivative GG-52 can prevent the induction of colitis by DDS, we next asked whether GG-52 could improve preformed DSSinduced colitis. For this experiment, GG-52 was administered via the rectal route. As shown in Table 2 , administration of GG-52 (100 mg/kg q.d.) attenuated clinical indices such as body weight change, colon length, and DAI significantly.
The Guggulsterone Derivative GG-52 Ameliorates TNBS-Induced Acute Murine Colitis
We used a murine model of TNBS-induced acute colitis to confirm anti-inflammatory effect of GG-52 on intestinal mucosa. As shown in Table 3 , administration of TNBSinduced experimental colitis that was characterized by increased clinical indices of colonic inflammation such as body weight changes and DAI. In this experimental model, pretreatment of GG-52 significantly reduced clinical indices in TNBS-treated mice. In addition, GG-52 resulted in a significant attenuation of acute colitis histologically (Figure 8a  and b) .
Comparison of the Preventive Effects of GG-52, Sulfasalazine, and Prednisolone in DSS-Induced Acute Colitis
We next asked how efficiently administration of GG-52 to prevent DSS-induced experimental colitis compared with well-known drugs used to treat IBD. For this experiment, a preventive murine model was used. As shown in Table 4 , In addition, histologic grading in GG-52-, sulfasalazine-, and prednisolone-treated mice was significantly reduced compared with DSS alone (Figure 9 ). However, the differences in clinical indices and histologic grading between treatment groups were not found significant (Table 4 ; Figure 9 ). These results suggest that GG-52 has an efficacy equal to that of the therapeutic drugs sulfasalazine and prednisolone.
DISCUSSION
In this study, the guggulsterone derivative GG-52 significantly suppressed NF-kB signaling in IEC. The inhibition of both IkB phosphorylation/degradation and NF-kB activation resulted in the downregulation of chemokine expression in COLO 205 cells stimulated with TNF-a. Moreover, GG-52 attenuated intestinal inflammation in two experimental murine colitis models. These findings indicate that oral and rectal administration of the novel guggulsterone derivative GG-52 has an anti-inflammatory effect on IBD. Although IBD is a chronic gut inflammatory condition of unknown etiology, mucosal immunity and epithelial permeability seem to be two interconnected etiological factors in the pathogenesis of IBD. Increased intestinal permeability can allow luminal antigens to penetrate the intestinal tissue and then these antigens are thought to activate and/or perpetuate the immune response. 30 Considering that the TNF-a-mediated increase in both inflammatory cytokines and intestinal permeability requires NF-kB activation, 10 suppression of NFkB activity may allow recovery from the production of excess levels of inflammatory cytokines and the increased epithelial permeability in IBD patients.
Although we have previously shown that guggulsterone has a preventive effect on DSS-induced colitis, 13 absorption of guggulsterone into the blood could potentially be harmful; guggulsterone may cause unexpected suppression of NF-kB activity in other tissues, which might augment inappropriate apoptosis. To diminish intestinal absorption and prolong the retention period in the gut lumen, we designed guggulsterone derivatives with increased lipophilicity and decreased solubility, and then biosynthesized four new derivatives. Among the derivatives, GG-50B and GG-52 inhibited the expression of chemokines IL-8 and MCP-1 by the blockade of NF-kB signaling in IEC, suggesting a possible mechanism for their anti-inflammatory actions in the intestine. In this study, guggulsterone derivatives did not completely inhibit the NF-kB activity in TNF-a-stimulated cells. As the expression of chemokine IL-8 and MCP-1 is regulated by transcriptional factor NF-kB and AP-1, it is possible that AP-1 signal may be involved in chemokine suppression in IECs treated with guggulsterone derivatives. Therefore, further study is needed to clarify whether AP-1 signaling is involved in chemokine suppression in guggulsterone derivatives-treated cells.
To clarify whether guggulsterone derivatives can modulate inflammation in the intestines of experimental animals, we used two murine preventive and therapeutic models of DSSinduced colitis; these models have several characteristics resembling those found in human ulcerative colitis and has proven useful for examining the pathophysiology underlying IBD. 26, 27 We showed that GG-52 could prevent DSS-induced acute colitis, whereas GG-50B partially improved the disease indices in colitis mice. In addition, GG-52 significantly attenuated the acute colitis in TNBS-induced experimental colitis. Furthermore, we showed that GG-52 ameliorated the established colitis in DSS-treated mice. In the next step, we studied acute toxicity of GG-52 in mice. Oral administration of GG-52 at a daily dose of 2000 mg/kg for 2 weeks did not result in any significant toxicity in mice. The value of no observed adverse effect level for GG-52 was 42000 mg/kg, that is, 10 times the maximum therapeutic dose. These results suggest that the guggulsterone derivative GG-52 has both protective and therapeutic effects on inflammation in the colon, indicating that it has a potential clinical value for the treatment of IBD. However, these findings should be further validated by studies using various different colitis models such as TNBS colitis and the IL-10 knock-out model, and chronic toxicity in mice. As sulfasalzine and corticosteroids, which are generally used for the treatment of IBD, have been shown to inhibit NF-kB signaling, [31] [32] [33] we evaluated how efficiently the guggulsterone derivative GG-52 could prevent DSS-induced experimental colitis compared with the former two drugs. We found that treatment with GG-52 has a comparable effect on the inhibition of colitis as sulfasalzine or prednisolone. Especially, GG-52 and sulfasalazine/5-ASA might have common features in the action of mechanism and formulation: blockade of NFkB signaling by targeting IKK and efficacy of topical administration. IKK can be related with the development of colitisassociated colon cancer 34 and sulfasalazine/5-ASA may reduce the risk of colorectal cancer in IBD patients. 35 Thus, further investigation is needed for the chemoprevention of by GG-52. In conclusion, a novel guggulsterone derivative GG-52 suppresses NF-kB signaling by targeting IKK and chemokine expression in IEC and attenuates intestinal inflammation in both preventive and therapeutic murine models. Therefore, GG-52 could be a potential therapeutic agent for the treatment of IBD. GG-52-induced attenuation of colitis JM Kim et al
